Evidence map›Paper›PMID 37842925›Full record

ArticleCardiovascular research2024

Prdm16 mutation determines sex-specific cardiac metabolism and identifies two novel cardiac metabolic regulators.

Jirko Kühnisch, Simon Theisen, Josephine Dartsch, Raphaela Fritsche-Guenther, Marieluise Kirchner, Benedikt Obermayer, Anna Bauer, Anne-Karin Kahlert, Michael Rothe, Dieter Beule and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Cardiovascular research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. PRDM16 Reduces Cellular Senescence by Upregulating GSTM1.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 2 countries.

Jirko KühnischCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID 0000-0003-4744-5421
Simon TheisenCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Josephine DartschCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID 0000-0002-7947-2881
Raphaela Fritsche-GuentherBIH Metabolomics Platform, Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-6965-0226
Marieluise KirchnerMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Proteomics Platform, Berlin, Germany.ORCID 0000-0002-7049-534X
Benedikt ObermayerCore Unit Bioinformatics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-9116-630X
Anna BauerBIH Metabolomics Platform, Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Berlin, Germany.
Anne-Karin KahlertDepartment of Congenital Heart Disease and Pediatric Cardiology, University Hospital of Schleswig-Holstein, Kiel, Germany.ORCID 0000-0002-3201-2642
Michael RotheLipidomix GmbH, Berlin, Germany.ORCID 0000-0002-6813-4705
Dieter BeuleMax Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.ORCID 0000-0002-3284-0632
Arnd HeuserMax Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.ORCID 0000-0002-3334-960X
Philipp MertinsMax-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Proteomics Platform, Berlin, Germany.ORCID 0000-0002-2245-528X
Jennifer A KirwanBIH Metabolomics Platform, Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-5423-1651
Nikolaus BerndtCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID 0000-0001-5594-9940
Calum A MacRaeHarvard Medical School and Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, USA.ORCID 0000-0001-5181-2664
Norbert HubnerMax Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.ORCID 0000-0002-1218-6223
Sabine KlaassenCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID 0000-0001-5925-9912
Max Delbrück Center · DEBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEBrigham and Women's Hospital · USHumboldt-Universität zu Berlin · DELipidomix (Germany) · DEUniversity Hospital Schleswig-Holstein · DE

Funding

Berlin Institute of HealthBundesministerium für Bildung und ForschungDeutsche ForschungsgemeinschaftDeutsche Forschungsgemeinschaft 422215721Deutsches Zentrum für Herz-Kreislauf-Forschung 81Z0100216Federal Ministry of Education and ResearchGerman Centre for Cardiovascular ResearchGerman Research Foundation 422215721
6 · The paper itself

Abstract

aimsMutation of the PRDM16 gene causes human dilated and non-compaction cardiomyopathy. The PRDM16 protein is a transcriptional regulator that affects cardiac development via Tbx5 and Hand1, thus regulating myocardial structure. The biallelic inactivation of Prdm16 induces severe cardiac dysfunction with post-natal lethality and hypertrophy in mice. The early pathological events that occur upon Prdm16 inactivation have not been explored. METHODS AND

resultsThis study performed in-depth pathophysiological and molecular analyses of male and female Prdm16csp1/wt mice that carry systemic, monoallelic Prdm16 gene inactivation. We systematically assessed early molecular changes through transcriptomics, proteomics, and metabolomics. Kinetic modelling of cardiac metabolism was performed in silico with CARDIOKIN. Prdm16csp1/wt mice are viable up to 8 months, develop hypoplastic hearts, and diminished systolic performance that is more pronounced in female mice. Prdm16csp1/wt cardiac tissue of both sexes showed reductions in metabolites associated with amino acid as well as glycerol metabolism, glycolysis, and the tricarboxylic acid cycle. Prdm16csp1/wt cardiac tissue revealed diminished glutathione (GSH) and increased inosine monophosphate (IMP) levels indicating oxidative stress and a dysregulated energetics, respectively. An accumulation of triacylglycerides exclusively in male Prdm16csp1/wt hearts suggests a sex-specific metabolic adaptation. Metabolic modelling using CARDIOKIN identified a reduction in fatty acid utilization in males as well as lower glucose utilization in female Prdm16csp1/wt cardiac tissue. On the level of transcripts and protein expression, Prdm16csp1/wt hearts demonstrate an up-regulation of pyridine nucleotide-disulphide oxidoreductase domain 2 (Pyroxd2) and the transcriptional regulator pre-B-cell leukaemia transcription factor interacting protein 1 (Pbxip1). The strongest concordant transcriptional up-regulation was detected for Prdm16 itself, probably through an autoregulatory mechanism.

conclusionsMonoallelic, global Prdm16 mutation diminishes cardiac performance in Prdm16csp1/wt mice. Metabolic alterations and transcriptional dysregulation in Prdm16csp1/wt affect cardiac tissue. Female Prdm16csp1/wt mice develop a more pronounced phenotype, indicating sexual dimorphism at this early pathological window. This study suggests that metabolic dysregulation is an early event in the PRDM16 associated cardiac pathology.

Indexed as

CardiomyopathiesHeartAnimalsDNA-Binding ProteinsFemaleMaleMiceMutationMyocardiumSex CharacteristicsTranscription FactorsDNA-Binding ProteinsPrdm16 protein, mouseTranscription FactorsCardiomyopathyMetabolismMutationPrdm16

Identifiers

PMID37842925
PMCPMC10874277
OpenAlexW4387661087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.